FierceBiotech21d
Arcus' new HIF-2a data in kidney cancer hint at potential edge over Merck's Welireg, analysts say
With new data out on Arcus Biosciences’ experimental HIF-2a inhibitor, one group of analysts figures the company could give Merck’s Welireg a run for its money in kidney cancer. In the phase 1 ...
Business Wire22d
First Clinical Data for Arcus Biosciences’ HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer
“Based on these data, casdatifan has the potential to be a future treatment option for kidney ... people with cancer live longer. Founded in 2015, the company has expedited the development ...